Category Archives: Inside BIO Industry Analysis

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of certainty for public exits, subsequent private financings, and even pharma licensing deals are over. IPOs have been out of favor for five years, venture firms are turning away from the sector, and fewer licensing deals are being cut. What is less understood about this uncertain environment is how it has forced management and their venture backers, to not only rethink Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Kinase Drug Development – Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last decade, but when we take a look at recent approvals and NDA filings there seems to be a strengthening of the field. There are now 16 kinase inhibitors that have been approved and five seeking regulatory approval in the next few months. The last two years in particular has been a boom for the KIs, with seven approvals, three of which target Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum: The New Kids on the Biotech Block

desert

Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off the 11th Annual BIO Investor Forum and focused on non-traditional early-stage investors and deal structures. Moderated by Jeron Eaves, a senior practice executive with Campbell Alliance, the panel highlighted companies that have secured financing from creative sources, like patient advocacy groups and venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How does the NBI perform in the last quarter of the year?

YTD-10-08-2012

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months of the year, or underperform? The NBI tends to be up in the 4th quarter, but a lot of that has to do with the overall market, not the biotechs. Here are the returns for the last quarter of the year for the last 20 years: (source: Factset) When looking directly at overall performance, biotech and the broader market have had good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Is the early-stage IPO making a comeback?

Stock Ticker

Yesterday was the NASDAQ debut for preclinical-stage biotech Regulus (RGLS). The microRNA platform company is working in multiple therapeutic areas and planning to reach the clinic in 2014. Since the start of the 2009 post-market crash window for biotech IPOs, there have been only two preclinical biotech companies to make it to the public stage. Back in January, we saw Verastem (VSTM), at only 1.5 years of age, make it to the NASDAQ and raise Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post